Characteristics of 10-year survivors of high-grade serous ovarian carcinoma

被引:79
作者
Dao, Fanny [1 ]
Schlappe, Brooke A. [1 ]
Tseng, Jill [1 ]
Lester, Jenny [2 ]
Nick, Alpa M. [3 ]
Lutgendorf, Susan K. [4 ,5 ]
McMeekin, Scott [6 ]
Coleman, Robert L. [3 ]
Moore, Kathleen N. [6 ]
Karlan, Beth Y. [2 ]
Sood, Anil K. [3 ]
Levine, Douglas A. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, 1275 York Ave, New York, NY 10065 USA
[2] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA
[3] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Dept Gynecol Oncol, Dept Canc Biol, Dallas, TX USA
[4] Univ Iowa, Holden Comprehens Canc Ctr, Dept Psychol & Brain Sci, Dept Obstet & Gynecol, Iowa City, IA 52242 USA
[5] Univ Iowa, Holden Comprehens Canc Ctr, Dept Urol, Iowa City, IA 52242 USA
[6] Univ Oklahoma, Dept Obstet & Gynecol, Stephenson Oklahoma Canc Ctr, Div Gynecol Oncol, Oklahoma City, OK USA
关键词
Ovarian cancer; Long-term survival; Neoadjuvant chemotherapy; Surgical cytoreduction; Outcome; Survival; PROGNOSTIC-FACTORS; CANCER; MORTALITY; SURGERY; DISEASE;
D O I
10.1016/j.ygyno.2016.03.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. High-grade serous carcinoma (HGSC) generally presents at an advanced stage with poor long-term (LT) survival. Here we describe clinical features found in women surviving HGSC for ten or more years. Methods. A multi-center research consortium was established between five participating academic centers. Patient selection criteria included high-grade serous ovarian, fallopian tube, or peritoneal carcinoma with at least ten years of follow up. Non-serous, borderline tumors and low-grade serous subtypes were excluded. Results. The 203 identified LT ten-year survivors with HGSC were diagnosed at a median age of 57 years (range 37-84 years). The majority of patients had stage IIIC (72.4%) disease at presentation. Of those who underwent primary cytoreductive surgery, optimal cytoreduction was achieved in 143 (85.6%) patients. After a median follow up of 144 months, 88 (46.8%) patients did not develop recurrent disease after initial treatment. Unexpected findings from this survey of LT survivors includes 14% of patients having had suboptimal cytoreduction, 11% of patients having an initial platinum free interval of <12 months, and nearly 53% of patients having recurrent disease, yet still surviving more than ten years after diagnosis. Conclusions. LT survivors of HGSC of the ovary generally have favorable clinical features including optimal surgical cytoreduction and primary platinum sensitive disease. The majority of patients will develop recurrent disease, however many remained disease free for more than 10 years. Future work will compare the clinical features of this unusual cohort of LT survivors with the characteristics of HGSC patients having less favorable outcomes. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:260 / 263
页数:4
相关论文
共 50 条
  • [1] Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma
    Bromley, Amy B.
    Altman, Alon D.
    Chu, Pamela
    Nation, Jill G.
    Nelson, Gregg S.
    Ghatage, Praful
    Kalloger, Steve E.
    Han, Guangming
    Koebel, Martin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2012, 31 (05) : 397 - 404
  • [2] Clinical Outcomes of Patients with High-Grade Ovarian Carcinoma Arising in Endometriosis Compared to Ovarian High-Grade Serous Carcinoma
    Yalcin, Ibrahim
    Sahin, Hanifi
    Sari, Mustafa Erkan
    Haberal, Asuman Nihan
    Sahin, Eda Adeviye
    Celik, Husnu
    Meydanli, Mehmet Mutlu
    Ayhan, Ali
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 19 (04)
  • [3] Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
    Marchocki, Zibi
    Tone, Alicia
    Virtanen, Carl
    de Borja, Richard
    Clarke, Blaise
    Brown, Theodore
    May, Taymaa
    JOURNAL OF OVARIAN RESEARCH, 2022, 15 (01)
  • [4] Spatially resolved transcriptomics of high-grade serous ovarian carcinoma
    Stur, Elaine
    Corvigno, Sara
    Xu, Mingchu
    Chen, Ken
    Tan, Yukun
    Lee, Sanghoon
    Liu, Jinsong
    Ricco, Emily
    Kraushaar, Daniel
    Castro, Patricia
    Zhang, Jianhua
    Sood, Anil K.
    ISCIENCE, 2022, 25 (03)
  • [5] Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma
    Chen, Gregory M.
    Kannan, Lavanya
    Geistlinger, Ludwig
    Kofia, Victor
    Safikhani, Zhaleh
    Gendoo, Deena M. A.
    Parmigiani, Giovanni
    Birrer, Michael
    Haibe-Kains, Benjamin
    Waldron, Levi
    CLINICAL CANCER RESEARCH, 2018, 24 (20) : 5037 - 5047
  • [6] Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
    Hwangbo, Suhyun
    Kim, Se Ik
    Kim, Ju-Hyun
    Eoh, Kyung Jin
    Lee, Chanhee
    Kim, Young Tae
    Suh, Dae-Shik
    Park, Taesung
    Song, Yong Sang
    CANCERS, 2021, 13 (08)
  • [7] Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma
    Kim, Se Ik
    Lee, Hyung-Chul
    Yoon, Hyun-Kyu
    Kim, Hee Seung
    Chung, Hyun Hoon
    Kim, Jae-Weon
    Park, Noh Hyun
    Song, Yong-Sang
    Lee, Maria
    BMC CANCER, 2022, 22 (01)
  • [8] Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence
    Tsonis, Orestis
    Gkrozou, Fani
    Vlachos, Konstantinos
    Paschopoulos, Minas
    Mitsis, Michail C.
    Zakynthinakis-Kyriakou, Nikolaos
    Boussios, Stergios
    Pappas-Gogos, George
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (24)
  • [9] Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer
    Fabbro, Michel
    Colombo, Pierre-Emmanuel
    Leaha, Cristina Marinella
    Rouanet, Philippe
    Carrere, Sebastien
    Quenet, Francois
    Gutowski, Marian
    Mourregot, Anne
    D'Hondt, Veronique
    Coupier, Isabelle
    Vendrell, Julie
    Vilquin, Paul
    Pujol, Pascal
    Solassol, Jerome
    Mollevi, Caroline
    CANCERS, 2020, 12 (08) : 1 - 14
  • [10] Molecular Management of High-Grade Serous Ovarian Carcinoma
    Punzon-Jimenez, Paula
    Lago, Victor
    Domingo, Santiago
    Simon, Carlos
    Mas, Aymara
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)